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Abstract
Background:  The mammalian FOXO (forkhead box, O subclass) proteins are a family of
pleiotropic transcription factors involved in the regulation of a broad range of cellular processes
critical for survival. Despite the essential and diverse roles of the FOXO family members in human
cells and their involvement in tumor pathogenesis, the regulation of FOXO expression remains
poorly understood. We have addressed the mechanisms underlying the high level of expression of
the FOXO1A gene in a cell line, PER-453, derived from a primitive neuroectodermal tumor of the
central nervous system (CNS-PNET).
Methods: The status of the FOXO1A locus in the PER-453 CNS-PNET cell line was investigated by
Southern blotting and DNA sequence analysis of the proximal promoter, 5'-UTR, open reading
frame and 3'-UTR. FOXO1A expression was assessed by conventional and quantitative RT-PCR,
Northern and Western blotting.
Results: Quantitative real-time RT-PCR (qRT-PCR) data indicated that after normalization to
ACTB mRNA levels, canonical FOXO1A mRNA expression in the PER-453 cell line was 124-fold
higher than the average level of five other CNS-PNET cell lines tested, 24-fold higher than the level
in whole fetal brain, and 3.5-fold higher than the level in fetal brain germinal matrix cells. No
mutations within the FOXO1A open reading frame or gross rearrangements of the FOXO1A locus
were detected. However, a single nucleotide change within the proximal promoter and several
nucleotide changes within the 3'-UTR were identified. In addition, two novel FOXO1A transcripts
were isolated that differ from the canonical transcript by alternative splicing within the 3'-UTR.
Conclusion: The CNS-PNET cell line, PER-453, expresses FOXO1A at very high levels relative to
most normal and cancer cells from a broad range of tissues. The FOXO1A open reading frame is
wild type in the PER-453 cell line and the abnormally high FOXO1A mRNA expression is not due
to mutations affecting the 5'-UTR or proximal promoter. Over expression of FOXO1A may be the
result of PER-453 specific epimutations or imbalances in regulatory factors acting at the promoter
and/or 3'-UTR.
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Background
The mammalian FOXO (forkhead box, O subclass) pro-
teins, FOXO1A, FOXO3A, FOXO4, and FOXO6, are a
family of transcription factors with complex and incom-
pletely understood functional profiles [1-3]. Members of
the family are involved in the regulation of a range of crit-
ical processes in mammalian cells, including prolifera-
tion, differentiation, apoptosis, metabolism, and
responses to oxidative stress and DNA damage [4]. While
some of these effects are due to reduced FOXO activity in
the nucleus in response to signalling through the PI3K/
Akt pathway [5], FOXO proteins integrate signals from
multiple pathways and regulate gene expression as com-
ponents of dynamic multi-protein complexes that vary
with cell type and context [6]. This functional complexity
is reflected both by the broad array of genes regulated by
FOXO transcription factors and the diversity of post trans-
lational modifications regulating FOXO protein-protein
interactions, intracellular location and degradation (for
reviews see [7,8]).
In light of the pleiotropic nature of FOXO proteins and, in
particular, the pivotal role of FOXO proteins as compo-
nents of both the PI3K/Akt and TGFβ [9] pathways, both
of which are frequently deregulated in cancer, it is not sur-
prising that aberrant FOXO activity has been implicated in
tumorigenesis [7]. Indeed, evidence is accumulating to
suggest that the FOXO genes represent a tumour suppres-
sor gene family [4]. In PTEN null prostate and glioblast-
oma cancer cell lines, reconstitution of nuclear FOXO1A
or FOXO3A expression can suppress proliferation and
induce senescence or apoptosis [10-12]. Data from the
analyses of human primary tumor specimens have impli-
cated the down regulation of FOXO1A expression in the
pathogenesis of prostate [13] and endometrial cancer
[14], as well as childhood alveolar rhabdomyosarcoma
[15]. Although the molecular mechanisms of FOXO1A
mediated tumor suppression are only partially under-
stood it is likely that down regulation or FOXO1A expres-
sion potentiates tumorigenesis via deregulation of
pathways that are context dependent. For example,
reduced FOXO1A expression may contribute to the patho-
genesis of glioblastoma through deregulation of TGFβ
cytostatic signalling in neuroepithelial cells [9] while
aberrant stoichiometry of FOXO1A-androgen receptor
interactions may promote AKT-dependent and -inde-
pendent survival of prostate cancer cells [13,16]. How-
ever, irrespective of cellular context, a complete
understanding of the tumor suppressive properties of
FOXO1A depends not only on the dissection of FOXO1A
function at the protein level, but also the mechanisms of
regulation of expression of FOXO1A mRNA.
The available data suggest that FOXO1A expression levels
are generally low in primitive neuroectodermal tumours
of the central nervous system (CNS-PNETs) [17]. How-
ever, our microarray expression analyses of CNS-PNET
specimens revealed a surprisingly high level of FOXO1A
expression in one CNS-PNET cell line relative to five other
CNS-PNET cell lines and two normal fetal brain speci-
mens. Although over expression of bona fide tumor sup-
pressor genes such as p16 and p53 in cancer specimens has
been reported [18,19] the molecular mechanisms by
which this occurs and the biological significance of this
phenomenon are poorly understood. Since FOXO1A is
considered to be a tumor suppressor gene, and little is
known about the regulation of FOXO1A mRNA expres-
sion levels in mammalian cells, we investigated the
molecular mechanisms underlying the high expression of
FOXO1A in the PER-453 CNS-PNET cell line.
Methods
Cell lines and control specimens
CNS-PNET cell culture conditions, and the origins and
characteristics of the pineoblastoma cell lines PER-452,
PER-453, and PER-480 have been described [20,21]. The
medulloblastoma cell lines, PER-547 and PER-568 were
established from biopsy specimens obtained from two
boys, four and six years of age respectively, treated at Prin-
cess Margaret Hospital, Perth, Western Australia. The
DAOY medulloblastoma cell line was obtained from Dr.
Phillip Jacobsen, Royal Perth Hospital, Perth, Western
Australia [22]. RNA was isolated from brain germinal
matrix from a male fetus aborted at 16-weeks and fetal
brain RNA (20 weeks gestation) was purchased (Clon-
tech). Informed consent for the use of fetal tissues for
research purposes was obtained for all individuals
involved in this study according to hospital and Austral-
ian National Health and Medical Research (NHMRC)
guidelines. The study was approved by the Princess Mar-
garet Hospital Institutional Ethics Review Board.
RNA extraction and microarray analysis
The procedure for RNA extraction, cRNA synthesis, and
hybridisation to Affymetrix HG-U133A GeneChips has
been described [23]. The microarray data were normalised
using the Affymetrix MAS 5.0 software and recommended
procedures.
cDNA Synthesis, conventional RT-PCR, and DNA 
sequencing
cDNAs were synthesised from 2 μg total RNA using an
oligo-dT primer and Omniscript RT kit (Qiagen) accord-
ing to the manufacturer's protocol. Primers for conven-
tional RT-PCR were designed using Primer Express™ 1.5
(PE Applied Biosystems) or MacVector™ 7.0r1 (Oxford
Molecular). Details are available on request. Most RT-
PCRs were performed with Taq Polymerase (Fisher Bio-
tech) with the addition of 5% DMSO in some cases. The
FailSafe PreMix Selection Kit (Epicentre) was employed toBMC Cancer 2007, 7:67 http://www.biomedcentral.com/1471-2407/7/67
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amplify the FOXO1A promoter and 5'-UTR which are par-
ticularly GC rich. A PTC-200 gradient cycler from
GeneWorks was used for all PCR.
Amplified products were purified using either a PCR
Clean Up (Qiagen) or Gel Extraction Kit (Qiagen). For
cloning we used a TOPO Cloning Kit (Invitrogen). PCR
a) FOXO1A Northern analysis Figure 1
a) FOXO1A Northern analysis. mRNA isolated from the PER-452, PER-453, and PER-547 CNS-PNET cell lines was 
screened with a 32P labelled FOXO1A RT-PCR product spanning FOXO1A exons 1 and 2 including part of the forkhead domain 
(see Fig. 2b). A prominent band of ~5.9 kb, and a weaker band of ~5.4 kb were clearly visible in the PER-453 lane and are indi-
cated by arrows on the upper right. Faint bands of similar sizes were visible in the PER-452 lane on the original autoradiograph 
and no signals in this size range were observed in the PER-547 lane. Molecular weight markers (nt) are included on the left. b) 
FOXO1A immunoblot. Total cell lysates from the PER-452, PER-453, and PER-480 CNS-PNET cell lines were screened 
with an antibody to FOXO1A. c) A ~78 kDa band, equivalent to the known size of wild type FOXO1A, is clearly visible in the 
PER-453 lane. A weak signal at 78 kDa was also detected in the PER-452 lane, and no signal was detected in the PER-480 lane. 
Equal proportions (~7%) of either the nuclear or cytoplasmic protein fractions isolated from the PER-453 cell line were also 
assessed with the FOXO1A antibody. FOXO1A protein was detected in both fractions with a greater proportion detectable in 
the nucleus. As fractionation controls the blot was re-probed with monoclonal antibodies to the predominantly cytoplasmic 
protein ACTB, and nuclear protein histone H1. Molecular weight markers (kDa) are included on the left. d) FOXO1A gene 
copy number analysis. Genomic DNA from the PER-453 cell line and two normal individuals was digested with EcoRI and 
analysed by Southern analysis using a FOXO1A specific cDNA probe. FOXO1A genomic fragments of 3320 bp and 613 bp are 
indicated by arrows in the top panel. To control for loading the blot was stripped and reprobed with a 32P labelled PCR prod-
uct mapping to chromosome 14q that was expected to be present at diploid levels in the three specimens (bottom panel).
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products or plasmid clones were sequenced using Big Dye
Terminator V3, and the Applied Biosystems (ABI) PRISM
3730 capillary sequencer.
Quantitative RT-PCR (qRT-PCR)
qRT-PCR assays were carried out using a primer and probe
set specific for human FOXO1A (ABI, Assay on Demand).
Aliquots of total RNA extracted for microarray analysis as
described above were used for qRT-PCR experiments
according to ABI protocols. qRT-PCRs were run on an ABI
7700 sequence detector. All qRT-PCR experiments were
carried out in duplicate and expression levels were nor-
malized to ACTB levels.
Northern blot analysis
PolyA+ mRNA was isolated using a Qiagen Oligotext
mRNA Mini Kit. mRNA (2 ug) was prepared with deion-
ized glyoxal, electrophoresed on a 1.2% agarose gel and
transferred in 20×SSC to Magna Neutral Membrane
(Osmonics Inc.). The membrane was probed with a gel
purified 32P labelled FOXO1A PCR product and autoradi-
ographed. The membrane was stripped and re-probed
with a 32P labelled ACTB cDNA probe as a loading con-
trol.
Immunoblots
Whole cell extract
Whole cell protein extracts were obtained from cell lines
PER-452, PER-453 and PER-480 using lysis buffer con-
a) The human FOXO1A locus Figure 2
a) The human FOXO1A locus. Genomic arrangement of the FOXO1A locus on chromosome 13q14.11, and position and 
sizes (3320 bp and 613 bp) of known EcoRI (E) restriction sites. b) Analysis of the PER-453 FOXO1A proximal pro-
moter. The positions of seven putative GC-boxes (shaded squares), an FHBE (shaded triangle), and the single G to A base 
change identified in the FOXO1A promoter are indicated (see Table 3 for more details). c) Schematic depiction of the 
FOXO1A mRNA. The FOXO1A open reading frame of 1965 bp (thick line), forkhead DNA binding domain (dotted line), and 
the location of the cDNA probe used for Northern and Southern analysis (thin line) are indicated below the map.
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taining 2 mM EDTA, 1.85 mg/ml iodoacetamide, 25 μg/
ml p-nitrophenylguanidinobenzoate, 10 μg/ml leupep-
tin, 10 μg/ml aprotinin and 0.5% Triton X-100. Protein
concentrations were determined using BioRad Protein
Assay reagent. Total protein (20 μg) was electrophoresed
on a 10% SDS PAGE gel and transferred to Hybond-C
super membrane (Amersham). The membrane was
blocked in 0.1% TBST/5% skim milk for 1 hr at RT and
incubated overnight at 4°C with FOXO1A antibody (Cat.
No. 9462, Cell Signaling Technology). Following wash-
ing, the membrane was incubated with anti-Rabbit HRP
(Amersham) for 2 hr at RT. The membrane was washed,
treated with ECL reagent (Amersham) for one minute and
exposed to ECL film (Amersham).
Nuclear and cytoplasmic extracts
Nuclear and cytoplasmic protein fractions were obtained
from the PER-453 cell line. Cells were resuspended in 0.5
ml of Buffer A (10 mM Hepes, 10 mM KCl, 0.1 mM EDTA,
0.1 mM EGTA, 1 mM DTT, 10 μg/ml aprotinin, 10 μg/ml
leupeptin, and 0.1 mM sodium vanadate), mixed gently
and incubated on ice for 15 minutes. The samples were
vortexed after addition of 55 μl 10% Nonidet-P-40, centri-
fuged for one minute at 4°C, and the supernatants col-
lected. The remaining pellets were resuspended in 100 μl
ice cold Buffer B (20 mM Hepes, 400 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 1 mM DTT, 10 μg/ml aprotinin, 10
μg/ml leupeptin, and 0.1 mM sodium vanadate), rocked
for ten minutes at 4°C, centrifuged, and the nuclear pro-
tein containing supernatant was collected and analyzed
(see above). To control for fractionation, the membrane
was re-blocked in TBST/10% skim milk, incubated with
antibodies to ACTB (Pan-Actin Ab-5, Neomarkers) or His-
tone H1 (AE4, Santa Cruz) at RT for 2 hr, washed and
incubated with anti-Mouse HRP (Amersham). The mem-
brane was washed, treated with ECL reagent, and exposed
to ECL film (see above). Chemiluminescence was assessed
by phosphoimagery (Fujifilm FLA-3000 phosphoimager)
and quantitation by densitometry was undertaken using
Fujifilm software (Image Gauge Version 4.22).
Southern blot analysis
Genomic DNA was extracted from cell lines using stand-
ard procedures and from peripheral blood lymphocytes
(PBLs) using the QIAamp DNA Blood Mini Kit (Qiagen).
DNA (15 μg) was digested with EcoR1 (New England
BioLabs) at 37°C, electrophoresed overnight on a 0.8%
agarose gel, and transferred to Hybond-N+ membrane
(Amersham) using 0.4 M NaOH. The membrane was
hybridized with the same gel purified 32P labelled cDNA
probe used for Northern analysis. To control for DNA
loading, the blot was stripped and re-probed with a chro-
mosome 14 specific genomic PCR product expected to be
present at normal diploid levels in the PER-453 cell line.
Hybridization signals were obtained by phosphoimagery
and densitometric analysis was undertaken as described
above for immunoblotting.
Luciferase assays
Wild-type and mutant genomic PCR products spanning
1161 bp of sequence from -866 to +296 relative to the
FOXO1A transcription start site were generated from PER-
453 and cloned into the luciferase vector, pGL3-basic
(Promega). Human embryonic kidney (HEK) cells were
transfected simultaneously with 400 ng of test plasmid
and β-galactosidase expressing transfection control plas-
mid pSV-β gal (Promega), using Lipofectamine 2000
according to the manufacturer's protocol (Invitrogen).
After 48 hours, luciferase and b-galactosidase activities
were assayed using the β-galactosidase enzyme assay sys-
tem with reporter lysis buffer (Promega) according to the
manufacturer's instructions. Assays were carried out in
duplicate and measurements of normalised luciferase
activity were obtained from two independent experi-
ments.
Results
Expression of FOXO1A mRNA and protein in CNS-PNET 
cell lines
We assessed the transcription profiles of five CNS-PNET
cell lines, whole human fetal brain (20 weeks), and
human fetal brain germinal matrix cells (16 weeks) using
Affymetrix HG-U133A microarrays. Analysis of the micro-
array data revealed a very high level of FOXO1A mRNA in
the PER-453 cell line relative to the other CNS-PNET cell
lines and normal fetal brain specimens (Table 1). Verifica-
tion of the microarray data using quantitative real-time
RT-PCR (qRT-PCR) indicated that after normalization to
ACTB mRNA levels, canonical FOXO1A mRNA expression
in the PER-453 cell line was 124-fold higher than the aver-
age level of the other five CNS-PNET cell lines, 24-fold
higher than the level in whole fetal brain, and 3.5-fold
higher than the level in fetal brain germinal matrix cells
(Table 1). We also assessed FOXO1A mRNA expression in
the PER-452, PER-453, and PER-547 CNS-CNS-PNET cell
lines by Northern blotting (Fig. 1a). A prominent signal at
~5.9 kb, consistent with the size of the wild type FOXO1A
transcript [24], and a lesser signal at ~5.4 kb were visible
in the PER-453 lane, while very faint signals of ~5.9 kb
and ~5.4 kb were visible on the original autoradiograph
for PER-452. FOXO1A  mRNA was undetectable in the
PER-547 cell line consistent with the qRT-PCR results.
ACTB  hybridisation signals indicated that an adequate
amount of mRNA was loaded in each lane.
To assess FOXO1A protein levels in CNS-PNET cell lines
PER-452, PER-453, and PER-480, whole cell lysates were
analyzed by immunoblotting (Fig. 1b). FOXO1A protein
was weakly detectable in the PER-452 cell line and was
prominent in the PER-453 cell line at approximately 78BMC Cancer 2007, 7:67 http://www.biomedcentral.com/1471-2407/7/67
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kDa. These data are consistent with the qRT-PCR results
and the expected molecular weight of the wild type
FOXO1A protein. No signal was observed in the PER-480
cell line consistent with undetectable FOXO1A mRNA lev-
els in this cell line as measured by qRT-PCR.
FOXO1A is a transcription factor that is known to shuttle
between the nucleus where it is functionally active, and
the cytoplasm where it is considered to be functionally
inactive, in response to changes in its phosphorylation
status. To assess the subcellular localisation of FOXO1A in
the PER-453 cell line we investigated nuclear and cyto-
plasmic fractions by immunoblotting. Screening with
control antibodies against the predominantly cytoplasmic
protein ACTB, and the nuclear histone protein H1, indi-
cated that the nuclear and cytoplasmic fractionation was
successful. Quantitative densitometry revealed that
FOXO1A protein levels were approximately 2.85 fold
higher in the nuclear fraction than in the cytoplasm (Fig.
1c).
Genetic analysis of the FOXO1A locus in the PER-453 cell 
line
To investigate the underlying mechanism for the high
expression of FOXO1A in the PER-453 cell line we carried
out a detailed analysis of the FOXO1A locus and cDNA
sequence. Classical cytogenetic analysis of the PER-453
genome has been reported previously [20] and recently
high-resolution array-CGH analysis of the PER-453 cell
line was completed. All metaphase spreads examined
were near diploid and copy number variations or gross
chromosomal rearrangements likely to affect the FOXO1A
gene on chromosome 13 were not detected using either
technique. A common mechanism associated with over-
expression of specific genes in cancer (generally onco-
genes), is gene amplification. Accordingly, we assessed
whether over-expression of FOXO1A in the PER-453 cell
line was associated with increased FOXO1A  gene copy
number that may not have been detected by cytogenetic
analysis. Genomic DNAs from the PER-453 cell line and
PBLs from two normal individuals were digested with
EcoRI and probed with a FOXO1A cDNA probe. Hybridi-
zation to two EcoRI restriction fragments of 3320 bp and
613 bp was observed as expected (Figs 1d and 2a).
Although there was a higher DNA loading in the PER-453
lane relative to the PBL control lanes as judged by the rel-
ative signals of the loading control probe, densitometry
followed by linear regression analyses revealed that there
were no significant differences between the ratios of
FOXO1A  hybridisation signal to control signals (p =
0.29)(Table 2). These data indicate that FOXO1A  gene
copy number is not increased in the PER-453 cell line.
Table 2: Densitometric analysis of the FOXO1A Southern blot hybridization signals in Fig. 1d.
Ratio FOXO1A/loading control
DNA source 613 bp signal 3320 bp signal
PER-453 1.32 1.13
PBL-3 1.46 1.27
PBL-4 1.37 1.12
Table 1: FOXO1A mRNA expression levels in CNS-PNET cell lines and normal fetal brain specimens.
EXPRESSION OF FOXO1A
Cell line/tissue MICROARRAY qRT-PCR N qRT-PCR
PER-452 228 0.57 0.65
PER-453 2324 19.89 23.86
PER-480 A 0.009 0.01
PER-547 A 0.006 0.01
PER-568 A 0.005 0.01
DAOY ND 0.21 0.24
FETAL BRAIN (FB) 428 0.87 1
GERMINAL MATRIX 887 5.9 6.78
FOXO1A mRNA expression levels based on microarray expression scores were obtained for CNS-PNET cell lines and controls using HG-U133A 
GeneChips (202724-s-at probe set, 3'-UTR specific). Relative expression levels were verified by qRT-PCR and are expressed relative to ACTB 
expression levels in each specimen. Normalised qRT-PCR (NqRT-PCR) levels are presented relative to fetal brain. A-absent call, ND-not 
determined.BMC Cancer 2007, 7:67 http://www.biomedcentral.com/1471-2407/7/67
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Sequence analysis of the FOXO1A gene
We hypothesised that the high FOXO1A mRNA expres-
sion in PER-453 cells may be the result of aberrant tran-
scriptional regulation due to mutations or rearrangements
in sequences upstream of the FOXO1A  open reading
frame or within the 3'-UTR. Schematic representations of
the organization of the FOXO1A locus at 13q14.11 and
the canonical FOXO1A cDNA sequence (GenBank acces-
sion no. NM_002015; [24]) are presented in Fig 2. We
generated a series of overlapping RT-PCR products cover-
ing 96% of the FOXO1A cDNA from PER-453. In addi-
tion, two overlapping genomic PCR products were
generated spanning the FOXO1A proximal promoter.
Identification of a single nucleotide change in the FOXO1A 
promoter
Genomic PCR products spanning 1161 bp of sequence
from -866 to +296 relative to the FOXO1A transcription
start site were generated from PER-453 and five other
CNS-PNET cell lines, three of which do not express
FOXO1A. All DNA sequences were identical except for a
single nucleotide difference (A to G) detected at position
-832 of one FOXO1A allele in the PER-453 cell line (Fig.
2b and Table 3).
We analysed the proximal promoter sequences 866 bp
upstream of the major FOXO1A transcription start site
[25] for transcription factor binding sites using MatIn-
spector [26]. Seven putative GC-boxes (GGGCGG) were
detected which may represent binding sites for transcrip-
tional regulators such as the specificity protein family
members, SP1-SP4 [27]. We also identified a consensus
forkhead-binding element (FHBE) (GTAAACAAA) [28] in
the FOXO1A proximal promoter at position -371 to -363
relative to the FOXO1A transcription start site (Fig. 2).
Identification of five single nucleotide changes and two 
splice variants in the FOXO1A 3'-UTR
The FOXO1A  mRNA has a particularly long 3'-UTR of
3356 nt representing nearly 60% of the length of the tran-
script (Fig. 2c). The extent of the FOXO1A 3'-UTR suggests
that this region may play an important role in the regula-
tion of FOXO1A transcript stability or translation. We did
not identify any gross rearrangements in the FOXO1A 3'-
UTR from PER-453 by DNA sequence analysis. However,
we identified five single nucleotide differences including
two previously identified SNPs (Table 3 and Fig. 3a). In
addition to the canonical cDNA sequence, we identified
two FOXO1A splice variants designated FOXO1A-2 and
FOXO1A-3, both of which are differentially spliced in a
manner consistent with the GT/AG rule from the same
splice donor site as the canonical transcript, 14 bp down-
stream from the stop codon within the 3'-UTR (Fig. 3b
and Fig 4). The sequences of these cDNAs were identical
to the canonical FOXO1A cDNA except for the splicing
out of 492 bp (extending from nt 2368 – 2859, FOXO1A-
2) and 526 bp (extending from nt 2368–2893, FOXO1A-
3)(Fig. 4). We did not obtain evidence for any other
FOXO1A alternative splicing events from any of our RT-
PCR analyses, which also included amplification of the
entire FOXO1A cDNA as two overlapping RT-PCR prod-
ucts. These data indicated that the FOXO1A-2  and
FOXO1A-3 cDNAs were derived from transcripts that were
identical to the canonical transcript except for the alterna-
tive splicing within the 3'-UTR. The lower signal intensity
and size of the ~5.4 kb molecular weight band relative to
the canonical ~5.9 kb transcript visible on the Northern
blot (Fig. 1a) was consistent both with the expected sizes
of the smaller alternative transcripts and the levels of the
RT-PCR products generated from the two splice variants
relative to the canonical FOXO1A RT-PCR product when
observed on ethidium bromide stained agarose gels (Fig.
3b).
Comparison of FOXO1A wild-type and mutant promoter 
activity
Luciferase assays were employed to assess the affect on
expression of the single A to G base change identified in
one allele of the FOXO1A promoter in the PER-453 cell
line. Linear regression analysis of the data from two inde-
pendent experiments carried out in duplicate indicated
Table 3: Nucleotide differences in the FOXO1A 3'-UTR.
DNA source Position of Base Change 
Relative to Transcriptional 
Start Site
Base Change Observed Published SNP NCBI – SNP 
Database Build 126
Promoter Region Clones -832 A/G No
PCR Product 2464 to 2474 single base insertion (A) Yes dbSNP: 11406284
PCR Product and Clone 2476 to 2486 single base deletion (A) No
PCR Product and Clone 2986 to 2994 single base deletion (A) Yes dbSNP: 3841231
PCR Product 4338 G/C No
4356 C/T No
Overlapping genomic or RT-PCR fragments were sequenced and compared to the canonical FOXO1A sequence (Genbank accession no. 
NM_002015).BMC Cancer 2007, 7:67 http://www.biomedcentral.com/1471-2407/7/67
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that the single nucleotide change had no significant affect
on promoter activity (p = 0.8).
Discussion
Despite the essential and diverse roles of the FOXO family
members in human cells, the regulation of FOXO expres-
sion is poorly understood. FOXO proteins are important
components of signalling nodes responsive to external
cellular cues, and compromised FOXO function and con-
sequent disruption of these nodes is strongly implicated
in tumorigenesis [7,9,29]. Most studies of the role of
FOXO proteins in carcinogenesis have concentrated on
the regulation of FOXO activity at the post-translational
level, especially with regard to nucleo-cytoplasmic shut-
tling in response to changes in FOXO phosphorylation
status. However, FOXO expression levels and the regula-
tion of FOXO transcription have received scant attention
in any context.
According to the microarray data the normalised FOXO1A
expression level (probeset 202724_s_at) in the PER-453
cell line was 5.4-fold higher than the FOXO1A level of
normal fetal brain. Furthermore, it was 4-fold higher than
the median expression level of FOXO1A in 73 different
human tissues (including normal fetal brain) and cell
lines that were assessed by others using HG-U133 Gene-
Chips [30]. Similarly, FOXO1A was generally expressed at
low levels in the 83 cancer specimens assessed by Su et al.
These data suggest that the expression level of FOXO1A in
the PER-453 cell line is exceptionally high relative to the
a) Summary of FOXO1A cDNA sequencing and analysis Figure 3
a) Summary of FOXO1A cDNA sequencing and analysis. The structures of two FOXO1A splice variants (FOXO1A-2 and 
FOXO1A-3) are indicated. Two previously identified (*), and three additional single nucleotide differences were identified (see 
Table 3 for more details). b) Identification of alternative FOXO1A transcripts. RT-PCR analysis of the PER-453 cell line 
using FOXO1A specific primers (see Fig. 2b) generated amplicons of 1364 bp (canonical FOXO1A), 872 bp (FOXO1A-2), and 838 
bp (FOXO1A-3). RT-PCR products were electrophoresed on 0.8% ethidium bromide stained agarose gels.
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a.
800
600
1000
1500
100bp
Ladder
PER-453
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FOXO1A-2
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levels in most normal and cancerous tissues. We were una-
ble to assess FOXO1A expression levels in the primary pin-
eoblastoma from which the PER-453 cell line was derived.
However, the primary specimen and cell line displayed
very similar immunophenotypes and ultrastructural char-
acteristics [20] suggesting that the cell line has not
diverged greatly from that of the primary tumor. Although
there have been no published studies specifically address-
ing FOXO1A  expression levels in CNS-PNETs, the vast
majority of primary CNS-PNET specimens assayed using
the superseded HG-UL95A GeneChip were called
"absent" for FOXO1A expression in the largest published
microarray study of 68 CNS-PNET specimens [17], sug-
gesting that FOXO1A expression is generally low in pri-
mary CNS-PNETs.
Chromosomal translocations involving FOXO  family
members have been described in human leukemias and
pediatric alveolar rhabdomyosarcomas [31]. In each case,
FOXO fusion proteins result from translocations generat-
ing chimeric transcripts encoding the N-terminal region of
the fusion partner (MLL  for the leukemias, and either
PAX3 or PAX7 for the rhabdomyosarcomas), and the C-
terminal portion of the FOXO  component. Hence, the
expression levels of the chimeric transcripts are presuma-
bly regulated through the 5' promoter sequences of the
various FOXO fusion partners in combination with the
FOXO 3'-UTR. These findings raise the possibility that the
FOXO1A  over-expression observed in the PER-453 cell
line could be the result of a fusion event. However, our
data suggest that this is unlikely. Immunoblotting analy-
DNA sequence of the alternatively spliced region of the FOXO1A 3'-UTR Figure 4
DNA sequence of the alternatively spliced region of the FOXO1A 3'-UTR. The alternatively spliced regions of the 
FOXO1A-2 and FOXO1A-3 variants are in plain text. DNA sequence flanking the spliced region is in bold. The alternatively 
spliced region of the FOXO1A-2 transcript is underlined and is 34 bp shorter than the region spliced from the FOXO1A-3 tran-
script. The FOXO1A stop codon is boxed. Primers used to amplify the alternatively spliced region are in italics and underlined 
with an arrow.
1561 GTCCTCACCT GGCACCATGA TGCAGCAGAC GCCGTGCTAC TCGTTTGCGC CACCAAACAC
1621 CAGTTTGAAT TCACCCAGCC CAAACTACCA AAAATATAca tatggccaat ccagcatgAG
1681 CCCTTTGCCC CAGATGCCTA TACAAACACT TCAGGACAAT AAGTCGAGTT ATGGAGGTAT
1741 GAGTCAGTAT AACTGTGCGC CTGGACTCTT GAAGGAGTTG CTGACTTCTG ACTCTCCTCC
1801 CCATAATGAC ATTATGACAC CAGTTGATCC TGGGGTAGCC CAGCCCAACA GCCGGGTTCT
1861 GGGCCAGAAC GTCATGATGG GCCCTAATTC GGTCATGTCA ACCTATGGCA GCCAGGCATC
1921 TCATAACAAA ATGATGAATC CCAGCTCCCA TACCCACCCT GGACATGCTC AGCAGACATC
1981 TGCAGTTAAC GGGCGTCCCC TGCCCCACAC GGTAAGCACC ATGCCCCACA CCTCGGGTAT
2041 GAACCGCCTG ACCCAAGTGA AGACACCTGT ACAAGTGCCT CTGCCCCACC CCATGCAGAT
2101 GAGTGCCCTG GGGGGCTACT CCTCCGTGAG CAGCTGCAAT GGCTATGGCA GAATGGGCCT
2161 TCTCCACCAG GAGAAGCTCC CAAGTGACTT GGATGGCATG TTCATTGAGC GCTTAGACTG
2221 TGACATGGAA TCCATCATTC GGAATGACCT CATGGATGGA GATACATTGG ATTTTAACTT
2281 TGACAATGTG TTGCCCAACC AAAGCTTCCC ACACAGTGTC AAGACAACGA CACATAGCTG
2341 GGTGTCAGGC TGAGGGTTAG TGAGCAGGTT ACACTTAAAA GTACTTCAGA TTGTCTGACA
2401 GCAGGAACTG AGAGAAGCAG TCCAAAGATG TCTTTCACCA ACTCCCTTTT AGTTTTCTTG
2461 GTTAAAAAAA AAAACAAAAA AAAAAACCCT CCTTTTTTTC CTTTCGTCAG ACTTGGCAGC
2521 AAAGACATTT TTCCTGTACA GGATGTTTGC CCAATGTGTG CAGGTTATGT GCTGCTGTAG
2581 ATAAGGACTG TGCCATTGGA AATTTCATTA CAATGAAGTG CCAAACTCAC TACACCATAT
2641 AATTGCAGAA AAGATTTTCA GATCCTGGTG TGCTTTCAAG TTTTGTATAT AAGCAGTAGA
2701 TACAGATTGT ATTTGTGTGT GTTTTTGGTT TTTCTAAATA TCCAATTGGT CCAAGGAAAG
2761 TTTATACTCT TTTTGTAATA CTGTGATGGG CCTCATGTCT TGATAAGTTA AACTTTTGTT
2821 TGTACTACCT GTTTTCTGCG GAACTGACGG ATCACAAAGA ACTGAATCTC CATTCTGCAT
2881 CTCCATTGAA CAGCCTTGGA CCTGTTCACG TTGCCACAGA ATTCACATGA GAACCAAGTA
2941 GCCTGTTATC AATCTGCTAA ATTAATGGAC TTGTTAAACT TTTGGAAAAA AAAAGATTAA
3001 ATGccagctt tgtacaggtc ttTTCTATTT TTTTTTGTTT ATTTTGTTAT TTGCAAATTT
3061 GTACAAACAT TTAAATGGTT CTAATTTCCA GATAAATGAT TTTTGATGTT ATTGTTGGGABMC Cancer 2007, 7:67 http://www.biomedcentral.com/1471-2407/7/67
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sis of the PER-453 cell line using a FOXO1A antibody that
recognizes an epitope C-terminal to the usual FOXO1A
fusion point revealed a prominent band of approximately
~78 kDa. This is consistent with the expected size of wild
type FOXO1A and is significantly smaller than FOXO1A-
PAX3/PAX7 (~97 kDa)[32], or FOXO-MLL (>200 kDa)
fusion proteins [33].
The lack of coding region mutations or rearrangements,
and the predominantly nuclear localization of the
FOXO1A protein are consistent with functionally normal
FOXO1A protein in PER-453 cells. In addition, our data
indicated that FOXO1A over-expression in the PER-453
cell line was not associated with gene amplification or a
translocation event and we did not detect gross rearrange-
ments of the FOXO1A proximal promoter, 5'-UTR, or 3'-
UTR. These results suggest that FOXO1A over-expression
may be the result of altered chromatin structure (e.g. his-
tone hyperacetylation) at the FOXO1A locus and/or aber-
rant regulation by factors acting in trans at the promoter
and/or 3'-UTR. The expression levels of several genes
flanking the FOXO1A locus were similar in each of the
CNS-PNET cell lines, suggesting that a generalised chro-
matin restructuring and/or coordinated deregulation of
genes in the region of 13q14.11 is unlikely to explain the
aberrant FOXO1A expression observed in the PER-453 cell
line. To date, there have been no detailed structural or
functional analyses of the promoters or 3'-UTRs of any
member of the FOXO family. Although the extent of the
human FOXO1A promoter has yet to be formally deter-
mined, our data confirm that the proximal promoter is
TATA-less and GC rich [25]. Genes with promoters of this
kind are often regulated, at least in part, by the trans acting
specificity factors SP1-SP4 [34]. In addition, the identifi-
cation of a FHBE in the FOXO1A promoter raises the pos-
sibility that forkhead transcription factors may be
involved in the regulation of FOXO1A message levels. A
more detailed analysis is required to determine whether
imbalances in SP and/or forkhead transcription factors are
associated with deregulated FOXO1A  expression in the
PER-453 cell line.
The luciferase data suggest that the A to G mutation iden-
tified in one allele of the FOXO1A promoter in the PER-
453 cell line is not associated with FOXO1A over-expres-
sion. Although we were unable to test the activities of the
luciferase reporter constructs in CNS-PNET cells because
of the low transfection efficiency of these cells, we consid-
ered that HEK cells represented a reasonable compromise
for our study because they are tumorigenic cells derived
from human foetal tissue and they express FOXO1A
mRNA at a level comparable to human foetal brain cells,
from which CNS-PNETs are thought to be derived. Over-
all, our data suggest that the high FOXO1A expression in
the PER-453 cell line is associated with imbalances in
transcription factor activity or epigenetic changes that are
specific to this cell line.
It is becoming increasingly clear that the 3'-UTRs of
eukaryotic transcripts can play important roles in the reg-
ulation of mRNA stability, localisation, and translation
[35], and aberrant 3'-UTR mediated regulation is involved
in oncogenesis [36]. We have identified two novel
FOXO1A transcripts in the PER-453 cell line that differ
from the canonical transcript through splicing out in their
3'-UTRs. Apart from the report of a low abundance alter-
native FOXO1A  transcript isolated from a human fetal
brain cDNA library and distinct from those described here
[24], this is the first demonstration of other alternatively
spliced FOXO1A transcripts in any cell type. It remains to
be seen whether these alternative FOXO1A transcripts are
brain tissue specific or present in other cell types, and
whether the alternatively spliced region is involved in the
regulation of transcript abundance and tissue specific
expression. A detailed analysis of the significance of
FOXO1A-2 and FOXO1A-3 expression in human cells may
provide new insights into the mechanisms by which
FOXO1A expression levels are finely coordinated in
response to diverse stimuli.
Although some of the specific 3'-UTR sequences and
trans-acting factors that are involved in these processes
have been determined, the precise mechanisms of 3'-UTR
mediated regulation of transcript abundance remain
poorly understood. An analysis of the canonical FOXO1A
3'-UTR sequence for known 3'-UTR regulatory elements
by UTRscan [37] revealed only a consensus Brd-box
(AGCTTA) and K-box (TGTGAT). These repressive ele-
ments, first described in the 3'-UTRs of multiple genes of
the enhancer of split complex in Drosophila, are thought to
be involved in miRNA mediated regulation of Notch sig-
nalling [38]. Interestingly, one of these elements, the K-
box, is not present in either of the alternatively spliced
FOXO1A transcripts that we detected in PER-453 cells. At
present, it is unknown whether mammalian Brd-box and
K-box elements are functionally similar to their insect
counterparts, and it remains to be determined whether
these elements play a role in miRNA-mediated regulation
of FOXO1A expression.
Although apparently paradoxical, high expression of bona
fide tumor suppressor genes, including p16 [18] and p53
[19], have been reported in solid tumor specimens. In the
latter study, high levels of wild type p53 were detected in
CNS-PNETs. These authors suggest that apoptosis that
would normally be induced by high p53 levels is counter-
balanced by elevated expression of anti-apoptotic Bcl-2 in
these tumors. It is possible that an analogous situation
exists in the PER-453 cell line whereby the tumor suppres-
sive effects of the high level of expression of wild typeBMC Cancer 2007, 7:67 http://www.biomedcentral.com/1471-2407/7/67
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FOXO1A are overridden by inactivation or deregulation
of downstream effector molecules.
Conclusion
The importance of FOXO family members as critical com-
ponents of signalling nodes implicated in the pathogene-
sis of a variety of tumor types suggests that the
modulation of FOXO expression and function may be a
useful approach for the treatment of some human cancers
[39,40]. On that basis, a greater understanding of FOXO
transcriptional regulation, as well as FOXO protein shut-
tling dynamics and post-translational modification, may
well provide new avenues for the design of novel therapies
targeting FOXO activity in cancer cells.
The CNS-PNET cell line, PER-453, expresses FOXO1A at
very high levels relative to most normal and cancer cells
from a broad range of tissues. The FOXO1A open reading
frame is wild type in the PER-453 cell line and the abnor-
mally high FOXO1A mRNA expression is not due to muta-
tions affecting the 5'-UTR or proximal promoter. Over
expression of FOXO1A may be the result of PER-453 spe-
cific epimutations or imbalances in regulatory factors act-
ing at the promoter and/or 3'-UTR.
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